Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.410
+0.070 (5.22%)
Jan 2, 2026, 12:09 PM EST - Market open
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$698,222
Market Cap
14.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 1 | 6.67% |
| Dec 31, 2023 | 15 | 0 | - |
| Dec 31, 2022 | 15 | 0 | - |
| Dec 31, 2021 | 15 | -3 | -16.67% |
| Dec 31, 2020 | 18 | 2 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNGX News
- 15 days ago - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PRNewsWire
- 15 days ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 16 days ago - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PRNewsWire
- 4 weeks ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 6 weeks ago - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 3 months ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire